The thyroid in childhood and adolescence is not simply a scaled-down version of the adult thyroid. Thyroid function directly contributes to neurocognitive maturation, somatic growth, bone mineralization, and the regulation of energy metabolism during developmental stages in which even relatively modest variations in hormonal signaling can produce clinically relevant effects. Newborns and infants depend on an adequate supply of T4 for myelination and neuronal differentiation, whereas in children and adolescents the thyroid interacts with the GH-IGF-1 axis and sex hormones to determine growth and pubertal trajectories.
In practical terms, pediatric thyroid disease includes conditions of major public health importance, such as congenital hypothyroidism detected through newborn screening, as well as conditions that are more frequent during school age and adolescence, including autoimmune thyroiditis and Graves’ disease. In addition to functional disorders, pediatric thyroid medicine includes age-specific areas, such as the distinct epidemiology and biology of thyroid nodules and differentiated thyroid carcinoma, which have dedicated patterns of presentation and management strategies.
The hypothalamic-pituitary-thyroid axis begins to function early, but its maturation is progressive and depends on the integration of central TRH and TSH secretion, thyroid hormone biosynthetic capacity, and iodine availability. In the newborn, the transition to extrauterine life is characterized by a physiological TSH peak and a consequent increase in T4 and T3, a phenomenon that contributes to thermogenic and metabolic adaptation. This surge makes it essential to interpret thyroid tests using age-specific reference intervals and according to the timing of sample collection, because a sample obtained too early or too late relative to the physiological window can alter the sensitivity and specificity of screening and diagnostic confirmation.
The most clinically relevant pediatric feature is the relationship between thyroid signaling and neurological development. The developing brain uses T4 as a precursor for the local production of T3 through deiodinases, and adequate tissue availability influences neuronal migration, synaptogenesis, and myelination. For this reason, untreated or late-treated congenital hypothyroidism is associated with intellectual disability and neuromotor disorders, whereas prompt and appropriately titrated treatment substantially reduces the risk of adverse neurodevelopmental outcomes. The central clinical concept is that, during this phase, time is a biological factor: the window for preventing damage is narrow, and delayed correction cannot completely reverse its consequences.
In children and adolescents, the thyroid interacts with longitudinal growth and puberty. Acquired hypothyroidism may present with growth deceleration, delayed bone age, and, in more prolonged cases, pubertal abnormalities. Hyperthyroidism, by contrast, accelerates bone turnover and may cause weight loss, increased appetite, tachycardia, nervousness, and worsening school performance, signs that often precede a formal diagnosis. Thyroid assessment must therefore consider the gland as part of an integrated system involving metabolism, the cardiovascular system, and psychological and behavioral development.
The physiological variability of thyroid test results is greater in pediatric patients than in adults. TSH tends to be higher in newborns and infants and stabilizes with age, while FT4 and FT3 follow age-dependent patterns, with reference ranges that change during growth and puberty. This has practical implications: an adult-centered interpretation may lead to inappropriate diagnoses and treatments, particularly in the context of subclinical hypothyroidism. Laboratory methods and analytical interferences are also relevant and require methodological consistency during follow-up, especially when abnormalities are mild and clinical decisions depend more on trends over time than on individual isolated measurements.
Iodine status is another critical factor because the pediatric thyroid is more sensitive to both iodine deficiency and iodine excess. In iodine deficiency, hormone synthesis becomes inefficient, causing an increase in TSH and hyperplastic stimulation of the gland. In the presence of iodine excess, particularly in newborns and infants, the autoregulatory response may promote transient hypothyroidism. Population-level prevention and caution regarding exposure to pharmacological iodine loads are therefore pediatric safety issues, rather than merely nutritional considerations.
In summary, pediatric thyroid medicine is based on three principles: recognizing critical periods of vulnerability, using age-specific reference ranges and assessment criteria, and integrating biochemical findings with growth, neurodevelopment, and the family context. This framework is necessary for the appropriate management of newborn screening, acquired thyroid dysfunction, and nodular and oncological thyroid disease during childhood and adolescence.
The epidemiology of pediatric thyroid disease is dominated by two major categories: congenital hypothyroidism and acquired autoimmune diseases. Congenital hypothyroidism is one of the most important endocrine disorders in terms of secondary prevention because newborn screening has transformed a historical cause of disability into a manageable condition when diagnosed early. Reported incidence varies among countries and screening programs, partly because of differences in recall thresholds and the increased identification of mild or transient forms. This phenomenon has clinical implications regarding the risk of overdiagnosis and the need for reassessment and reclassification over time.
Autoimmune thyroid disease increases in frequency with age and becomes more common during school age and adolescence, with a higher prevalence among females and associations with other autoimmune conditions, particularly type 1 diabetes mellitus and celiac disease. In many cases, autoimmune thyroiditis presents with goiter and preserved thyroid function or with subclinical hypothyroidism and may progress to overt hypothyroidism over time. Family history, autoantibody titers, and ultrasound findings help stratify the risk of progression and guide follow-up and counseling.
Genetic determinants are particularly relevant in congenital hypothyroidism. Causes include thyroid dysgenesis, such as agenesis, ectopia, and hypoplasia, as well as defects in thyroid hormone biosynthesis involving iodide transport, organification, and thyroglobulin synthesis. These are accompanied by rarer central forms in which the defect is pituitary or hypothalamic, and by transient forms related to maternal antibodies, iodine exposure, or prematurity. Awareness of this heterogeneity is essential because it determines different diagnostic pathways and, most importantly, influences the likelihood of functional recovery and the need for permanent treatment.
Iodine status remains a major environmental determinant. In iodine-sufficient populations, severe iodine deficiency is uncommon, but borderline situations and at-risk subgroups persist, particularly where adherence to iodized salt use is limited or restrictive diets are followed. In newborns and infants, iodine excess may cause transient hypothyroidism through autoregulatory blockade, a clinically relevant consideration following exposure to iodine-containing antiseptics or contrast agents. Pediatric management therefore requires balance: documented deficiencies should be corrected while unnecessary exposures that may destabilize an immature thyroid should be avoided.
A specific area concerns the increased risk of thyroid carcinoma in predisposing conditions, including exposure to ionizing radiation and selected genetic syndromes. During childhood, the thyroid is more radiosensitive, and the relative risk of developing thyroid nodules and carcinoma after irradiation is higher than in adults. This explains why a history of cervical or mediastinal radiotherapy and exposure to nuclear accidents or radioactive contamination are central elements of the medical history. In these populations, surveillance should be targeted and based on ultrasound and endocrinological assessment, avoiding both clinical inertia and indiscriminate overscreening that could increase unnecessary procedures.
From an operational perspective, pediatric risk assessment requires the integration of genetics, environment, and immunity. Clinicians must be able to identify children at risk of permanent congenital hypothyroidism, children whose autoimmune disease is likely to progress, and children with conditions that predispose them to thyroid nodules and carcinoma. This enables personalized care that reduces diagnostic delays while limiting unnecessary treatment in transient conditions or disorders with little clinical impact.
Newborn screening for congenital hypothyroidism is one of the most effective interventions in pediatric preventive medicine. Its purpose is to identify newborns with deficient T4 production before evident clinical signs develop, because presentation may be subtle during the first weeks of life and the window for preventing neurodevelopmental damage is limited. Screening strategies include programs based on TSH, T4, or combinations of both, with differences among countries and regions. Each strategy involves trade-offs between sensitivity for primary hypothyroidism, the ability to detect central forms, and the recall rate.
Following an abnormal screening result, rapid action is the fundamental clinical principle. Serum TSH and FT4 are measured for confirmation, avoiding delays that could postpone treatment initiation. Clinical recommendations and evidence summaries emphasize the importance of starting levothyroxine as soon as possible in highly probable cases, ideally within the first two weeks of life, because neurocognitive benefit is maximized when exposure to hypothyroidism is minimized.
Once hormone deficiency has been confirmed, the next step is to distinguish permanent from transient forms and, whenever possible, determine the etiology. Thyroid dysgenesis is often associated with permanent hypothyroidism and may be identified through dedicated imaging, whereas defects in hormonogenesis may present with goiter and require a more detailed diagnostic pathway, including biochemical assessment and, in specialized centers, genetic testing. Transient forms include hypothyroidism caused by iodine exposure, maternal TSH receptor-blocking antibodies, prematurity, or critical neonatal illness. These conditions require careful follow-up to prevent both premature treatment withdrawal in permanent disease and unnecessary continuation in patients who recover thyroid function.
Central hypothyroidism is a distinct and rarer diagnosis because TSH may not be elevated despite a reduced FT4 concentration. This explains why screening programs based exclusively on TSH may fail to identify some central forms. In these cases, presentation may include other signs of hypopituitarism, such as hypoglycemia, cholestasis, or micropenis in males, and assessment must be extended to the other pituitary axes. The approach is multidisciplinary and requires particular attention to safety because a concomitant ACTH deficiency modifies initial management and requires protocols aimed at preventing acute adrenal insufficiency.
Levothyroxine treatment in newborns requires precision. The objectives are to normalize FT4 rapidly and bring TSH into age-appropriate ranges while avoiding both undertreatment and iatrogenic hyperthyroidism, which may be associated with irritability, tachycardia, and excessive acceleration of bone maturation. Dose titration must be supported by frequent biochemical monitoring during the first weeks, followed by scheduled assessments. Consensus guidelines emphasize that follow-up is not a secondary detail but an integral component of screening effectiveness because early diagnosis provides benefit only when followed by adequate treatment and systematic monitoring.
Reassessment to distinguish permanent from transient disease is a crucial step. In many clinical settings, reassessment is performed after 2 or 3 years of age, when the neurodevelopmental risk associated with a controlled treatment withdrawal is lower. The strategy is adapted according to initial severity, imaging findings, required dose, and the course of TSH over time. The decision must be individualized and explained to the family because treatment adherence and continuity also depend on understanding its rationale and future benefits. Congenital hypothyroidism therefore represents a model of care that integrates prevention, etiological diagnosis, treatment, and transition from pediatric to adult care, particularly in permanent cases requiring lifelong treatment.
Autoimmune thyroiditis, often referred to as Hashimoto thyroiditis, is the most common cause of acquired hypothyroidism in pediatric patients. Its clinical presentation may be subtle and include goiter, fatigue, growth deceleration, weight gain, constipation, reduced school performance, or nonspecific symptoms. Many children are diagnosed during assessment for goiter or through screening prompted by family history or other autoimmune diseases. Biochemical findings may show euthyroidism with positive antibodies, subclinical hypothyroidism, or overt hypothyroidism. Ultrasound frequently reveals a heterogeneous and hypoechoic pattern consistent with chronic inflammation and is particularly useful when autoimmunity is seronegative or when coexisting nodules require separate assessment.
The clinical management of autoimmune thyroiditis centers on three questions: when to treat, how to monitor, and how to manage goiter and associated conditions. Levothyroxine treatment is indicated in overt hypothyroidism and, in many situations, in subclinical hypothyroidism when TSH remains persistently elevated, compatible symptoms are present, goiter is progressive, or growth is affected. In mild and stable forms, particularly in the absence of symptoms and with normal growth, observational follow-up with periodic monitoring is often appropriate because a substantial proportion of patients remain stable or progress slowly. The decision must always include an assessment of linear growth, puberty, bone age when indicated, and psychological well-being because the clinical benefit of treating a mild biochemical abnormality depends on the individual context.
Graves’ disease is the main cause of autoimmune hyperthyroidism in pediatric patients. It is less common than in adults but clinically important because of its effects on behavior, sleep, school performance, and the cardiovascular system. Clinical features include tachycardia, tremor, weight loss despite increased appetite, irritability, heat intolerance, diarrhea, and sometimes ocular signs. In children and adolescents, neurobehavioral symptoms may dominate the presentation and delay diagnosis when they are interpreted as psychological or school-related problems. Diagnosis is biochemical, with suppressed TSH and elevated FT4 or FT3, and is supported by positive TRAb.
The management of pediatric Graves’ disease is complex because it requires a balance between efficacy, long-term safety, and family preferences. European guidelines emphasize that the available treatment options are antithyroid medications, radioiodine, and surgery, but their risks and benefits differ from those in adults. In pediatric patients, antithyroid medications are often the initial treatment, with careful monitoring for adverse reactions and a structured follow-up program. The decision to proceed to definitive treatment depends on response, recurrence, adherence, adverse effects, and the overall clinical context.
Rapid control of cardiovascular and autonomic symptoms is an important practical consideration. Beta-blockers have a bridging role in controlling tachycardia and tremor but do not replace specific treatment. Monitoring must include growth and puberty because hyperthyroidism may accelerate bone maturation and impair attainment of target height if it persists. Bone health also requires attention because increased turnover may reduce bone mineral density during a critical phase in the acquisition of peak bone mass.
Overall, pediatric autoimmune thyroid disease requires careful attention to timing and follow-up. The objective is not merely to normalize a laboratory value but to protect growth, neuropsychological development, and quality of life, while preventing both prolonged exposure to hypothyroidism or hyperthyroidism and the risks associated with unnecessary or excessively aggressive treatment. Continuity of care and family education are essential because adherence and the ability to recognize recurrence or deterioration also depend on support and understanding of the relevant clinical signs.
Thyroid nodules are less common in children than in adults, but they have a relatively higher probability of malignancy. For this reason, the pediatric approach cannot simply replicate adult management. Assessment should begin with a targeted medical history because several factors substantially modify risk, including exposure to ionizing radiation, a family history of thyroid carcinoma or predisposing syndromes, rapid nodule growth, lymphadenopathy, and compressive symptoms. Physical examination assesses consistency, fixation, and cervical lymph nodes, but risk stratification depends primarily on ultrasound findings, including echogenicity, margins, microcalcifications, shape, vascularity, and the presence of suspicious lymph nodes.
The American Thyroid Association guidelines for thyroid nodules and differentiated thyroid carcinoma in pediatric patients emphasize that cervical ultrasound is central to assessment and that fine-needle aspiration should be used selectively, guided by ultrasound characteristics and size. Because the risk profile differs from that of adults, thresholds require particular caution. Management must also include systematic lymph node assessment because lymph node involvement at diagnosis is more common in children, even though the long-term prognosis of differentiated thyroid carcinoma is often favorable when appropriately treated.
When cytology suggests malignancy or a high degree of suspicion, therapeutic planning requires accurate preoperative staging and surgery performed in experienced centers because the risk of complications, including recurrent laryngeal nerve injury and hypoparathyroidism, is also influenced by procedural volume and surgical expertise. Pediatric surgical strategies must balance the need for disease control against the reduction of long-term morbidity, a particularly important consideration because a child may live for many decades with the functional consequences of treatment.
Pediatric differentiated thyroid carcinoma often presents with greater locoregional extension and more frequent lymph node involvement than in adults, but mortality is generally low. This clinical paradox requires an approach that does not underestimate disease extent while also avoiding overtreatment, particularly regarding radioiodine use. Pediatric American Thyroid Association guidelines place considerable emphasis on risk stratification and on selecting patients for whom postoperative radioiodine is appropriate, specifically to reduce unnecessary exposure and potential late effects.
A specific issue concerns nodules arising in the setting of autoimmune thyroiditis. Thyroiditis can produce pseudonodules and ultrasound abnormalities that complicate interpretation. In these cases, the quality of ultrasound assessment and longitudinal follow-up become fundamental decision-making tools because morphological stability and the absence of suspicious features reduce the need for invasive procedures, whereas the emergence of high-risk characteristics requires a complete diagnostic pathway. The central clinical message is that pediatric care requires diagnostic precision and therapeutic caution, supported by experienced centers, to prevent both harmful delays and excessive interventions with long-term functional consequences.
The diagnosis of thyroid disorders in pediatric patients must be developed as a structured pathway rather than based on an isolated laboratory result. First-line testing includes TSH and FT4, with FT3 measured when hyperthyroidism is suspected or when FT4 is borderline and the clinical presentation is suggestive. Second-line testing includes autoantibodies, particularly TPOAb and TgAb for autoimmune thyroiditis and TRAb for Graves’ disease. This combination allows the etiology to be established in most cases without invasive testing. At the same time, the medical history should cover growth, weight trends, sleep, school performance, family histories of autoimmune and oncological disease, exposure to iodine and radiation, and medications or supplements that may interfere with thyroid function or treatment absorption.
Pediatric physical examination has different characteristics from adult assessment because signs may be less pronounced and more easily confused with normal developmental variability. Systematic evaluation should include heart rate and blood pressure, skin and hair, reflexes, tremor, signs of hyperactivity, and especially accurate anthropometric assessment plotted on growth charts. Growth velocity is a sensitive indicator of chronic thyroid dysfunction and often changes before symptoms are subjectively recognized. Pubertal assessment is equally important because both hypothyroidism and hyperthyroidism may alter the timing and progression of puberty and affect bone age.
Thyroid ultrasound is the principal imaging method. It is useful for evaluating goiter, the pattern of autoimmune thyroiditis, nodules, and lymph nodes. In congenital hypothyroidism, imaging may include ultrasound and, in selected settings, scintigraphy with appropriate tracers to determine the presence, location, and uptake of thyroid tissue. However, the priority remains the prompt initiation of treatment without delays caused by nonurgent diagnostic investigations. This principle is emphasized in consensus guidelines on congenital hypothyroidism, which place neurodevelopmental protection at the center of clinical management.
Follow-up should be structured according to the stage of care. In newborns with congenital hypothyroidism, monitoring is frequent during the first weeks and months, with clear biochemical and clinical objectives and attention to adherence, administration methods, and growth. In children with autoimmune thyroiditis, follow-up focuses on progression and the need for treatment, with intervals adjusted according to TSH, FT4, symptoms, growth, and thyroid size. In adolescents with Graves’ disease, follow-up is more intensive during antithyroid medication titration and response assessment and includes clinical and laboratory monitoring together with vigilance for adverse events.
Family and patient education is a substantial component of pediatric follow-up. Correct levothyroxine administration, management of interactions with iron and calcium, recognition of signs of hypothyroidism and hyperthyroidism, and understanding of treatment goals reduce instability, inappropriate healthcare use, and anxiety. During adolescence, the transition toward independent treatment management is a vulnerable phase and requires an explicit plan because adherence may decline and the disease may worsen silently, particularly in subclinical forms or when medications are discontinued without medical consultation. Guidelines on congenital hypothyroidism emphasize that transition of care is part of the right to a structured pathway because many conditions are chronic and persist throughout the life course.
The treatment of pediatric thyroid dysfunction is based on a common objective: ensuring thyroid hormone signaling that is appropriate for development while minimizing short-term and long-term iatrogenic risks. In hypothyroidism, levothyroxine is the standard treatment. In congenital hypothyroidism, treatment urgency is greatest: therapy must be started rapidly after confirmation, using doses sufficient to normalize FT4 promptly and bring TSH into the appropriate range. The 2020-2021 consensus guidelines for congenital hypothyroidism provide detailed recommendations on timing, initial doses, biochemical targets, and monitoring frequency, emphasizing that screening effectiveness depends on the quality of treatment and follow-up.
In children and adolescents with acquired hypothyroidism, replacement treatment is titrated according to weight, age, biochemical severity, and clinical objectives, with particular attention to growth and puberty. A pediatric-specific risk is chronic iatrogenic hyperthyroidism, which may accelerate bone maturation and reduce final height. This requires cautious titration, regular monitoring, and dose adjustment as body weight and growth phases change. Pharmacological and nutritional interactions must be managed systematically because variability in absorption may be mistakenly interpreted as biological instability of the disease.
In autoimmune hyperthyroidism, antithyroid medications are often the initial treatment. Pediatric management requires balancing control of hyperthyroidism against the prevention of adverse effects. Clinical and laboratory monitoring is essential and must include attention to symptoms suggestive of treatment-related complications. European guidelines on pediatric Graves’ disease address the duration of medical treatment, predictors of remission, criteria for considering definitive treatment, and the management of orbitopathy when present.
Thyroid surgery in pediatric patients requires extensive expertise. It is indicated in differentiated thyroid carcinoma, selected cases of Graves’ disease with recurrence or medication intolerance, and suspicious or compressive nodules. Surgical decisions must be based on accurate staging and a plan designed to minimize morbidity because complications such as hypoparathyroidism or dysphonia may have permanent consequences. Pediatric American Thyroid Association guidelines provide detailed recommendations regarding preoperative assessment, the extent of surgery, and follow-up to reduce recurrence and complications.
Radioiodine treatment in pediatric patients is a sensitive issue because it involves radiation exposure and potential late effects. In Graves’ disease, it may be considered in selected circumstances and at an appropriate age, but the decision must be shared and based on the balance between risks and benefits, available alternatives, and patient and family preferences. In differentiated thyroid carcinoma, postoperative radioiodine use is guided by risk stratification and should not be automatic, specifically to reduce overtreatment and long-term consequences. Pediatric American Thyroid Association guidelines emphasize this principle and support a more precise and less uniform approach than in the past.
Treatment adherence is a cross-cutting issue. Pediatric care requires practical adaptations, including appropriate formulations and administration methods for infants, treatment management in the school environment, and the gradual transfer of responsibility to adolescents. The quality of care often depends more on these factors than on pharmacological details because inconsistent administration is a frequent cause of biochemical instability and symptoms. Pediatric thyroid treatment is therefore a combination of pharmacology, education, and structured follow-up, with the objective of protecting overall long-term development.
The complications of pediatric thyroid disease are not limited to acute events but mainly involve long-term effects on growth and development. In congenital hypothyroidism, the most severe historical complication is neurocognitive impairment, which can now be prevented in most cases through early screening and treatment. Nevertheless, outcomes depend on initial severity, the timing of treatment initiation, dose adequacy, and the quality of follow-up. Excessive caution resulting in insufficient doses and slow normalization leaves a residual risk, whereas chronic overtreatment may affect behavior and skeletal maturation. The 2020-2021 consensus recommendations specifically emphasize the importance of prompt biochemical targets and scheduled monitoring.
In acquired thyroid dysfunction, the most frequent complication is the effect on growth and school performance. Chronic hypothyroidism slows growth velocity and may reduce final height when not recognized, whereas hyperthyroidism accelerates bone maturation and may compromise attainment of target height. Both conditions may also affect sleep, mood, attention, and academic performance, with consequences for family quality of life. It is therefore essential to integrate endocrinological follow-up with auxological monitoring and assessment of psychological well-being, particularly during adolescence, when anxiety and mood disorders may coexist and obscure endocrine symptoms.
In pediatric Graves’ disease, complications include recurrence after medical treatment, the need for definitive treatment, and, less commonly, orbitopathy with aesthetic and functional effects. European guidelines emphasize that treatment must also account for atypical presentations dominated by behavioral symptoms and declining performance because delayed diagnosis prolongs exposure to hyperthyroidism and increases the risk of complications.
In nodular and oncological disease, complications are related to both the condition and its treatment. Differentiated thyroid carcinoma in pediatric patients generally has a favorable prognosis but may present with more extensive disease and require complex surgery. Surgical complications and the effects of any radioiodine treatment require long-term follow-up, including surveillance for recurrence, management of post-thyroidectomy hypothyroidism, and attention to late effects. Pediatric American Thyroid Association guidelines emphasize the role of risk stratification and personalized follow-up in reducing morbidity and improving outcomes.
Transition to adult care is a crucial aspect of quality of life. Many pediatric patients with thyroid disease require continuity of care for decades. Transition should not be a simple administrative transfer but a structured process during which patients acquire knowledge and skills regarding treatment, therapeutic objectives, warning signs, and the importance of adherence. The absence of a structured transition increases the risk of treatment discontinuation, loss to follow-up, and recurrence of thyroid dysfunction, with effects on education, employment, and future reproductive health. Recommendations on congenital hypothyroidism explicitly recognize the right to a well-planned transition process.
In summary, the success of pediatric thyroid endocrinology is measured not only by biochemical normalization but also by functional outcomes: appropriate neurodevelopment, harmonious growth, physiological puberty, psychological well-being, and autonomy in disease management. Achieving these objectives requires long-term follow-up, effective communication with families and schools, and proportionate treatment choices that consider remaining life expectancy and the prevention of iatrogenic complications.